The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 04, 2010
Filed:
Dec. 04, 2007
Dihua Yu, Houston, TX (US);
Jun Yao, Chestnut Hill, MA (US);
Christopher L. Neal, Houston, TX (US);
Wentao Yang, Shanghai, CN;
Xiaoyan Zhou, Shanghai, CN;
Raphael E. Pollock, Houston, TX (US);
Mien-chie Hung, Houston, TX (US);
Jun Yang, Houston, TX (US);
Ping LI, Houston, TX (US);
Nina T. Nguyen, Houston, TX (US);
Dihua Yu, Houston, TX (US);
Jun Yao, Chestnut Hill, MA (US);
Christopher L. Neal, Houston, TX (US);
Wentao Yang, Shanghai, CN;
Xiaoyan Zhou, Shanghai, CN;
Raphael E. Pollock, Houston, TX (US);
Mien-Chie Hung, Houston, TX (US);
Jun Yang, Houston, TX (US);
Ping Li, Houston, TX (US);
Nina T. Nguyen, Houston, TX (US);
Board of Regents, The University of Texas System, Austin, TX (US);
Abstract
Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer.